Nafarelin
Nafarelin is a synthetic GnRH agonist with a D-Nal(2)6 substitution, approximately 200x more potent than native GnRH. Marketed exclusively as an intranasal spray (Synarel, Pfizer), it is FDA-approved for endometriosis and central precocious puberty, and widely used for IVF long-protocol downregulation.
Overview
Nafarelin was developed by Syntex (later acquired by Roche, then marketed by Pfizer) in the 1980s as part of the systematic exploration of D-amino acid substitutions at position 6 of the GnRH decapeptide. The 2-naphthylalanine substitution was selected for its exceptional enhancement of receptor binding affinity, producing a molecule approximately 200 times more potent than native GnRH — the highest potency among first-generation GnRH agonists. This extreme potency compensates for the low intranasal bioavailability (~2.8%), enabling effective clinical use via nasal spray alone without requiring injection formulations. Nafarelin received FDA approval for endometriosis in 1990 and for central precocious puberty in 1993, and remains widely used in IVF programs globally.
Mechanism of Action
Nafarelin binds the GnRH receptor (GnRHR) on anterior pituitary gonadotroph cells with approximately 200-fold greater affinity than native GnRH. The large hydrophobic 2-naphthyl group at position 6 both protects against endopeptidase cleavage at the Gly6-Leu7 bond and enhances hydrophobic interactions within the GnRHR binding pocket. Upon initial intranasal administration, nafarelin stimulates an acute surge in LH and FSH (flare response), transiently increasing sex steroid levels. With continued twice-daily dosing, sustained GnRHR occupancy drives receptor internalization and downregulation at the transcriptional level. By 2-4 weeks of continuous administration, gonadotropin secretion is suppressed to prepubertal or postmenopausal levels, with corresponding suppression of estradiol (women) or testosterone (men).
Reconstitution Calculator
Research
Uterine Fibroids
Nafarelin creates a hypoestrogenic environment that causes shrinkage of uterine fibroids (leiomyomas) — typically 40-60% volume reduction over 3-6 months. This is primarily used as presurgical adjuvant therapy to reduce fibroid size and vascularity before myomectomy or hysterectomy, facilitating less invasive surgical approaches and reducing operative blood loss.
Endometriosis
The pivotal trial by Henzl et al. (1988) compared nafarelin nasal spray (400 mcg/day) to danazol (800 mg/day oral) in women with laparoscopically confirmed endometriosis over 6 months. Nafarelin demonstrated equivalent efficacy in reducing revised AFS scores and relieving pain symptoms (dysmenorrhea, pelvic pain, dyspareunia) but with significantly fewer androgenic side effects than danazol — no weight gain, acne, or hirsutism. This trial was pivotal for FDA approval and established intranasal GnRH agonist therapy as a viable alternative to oral androgens.
Central Precocious Puberty
Nafarelin is FDA-approved for central precocious puberty (CPP) at doses of 1600 mcg/day (two sprays per nostril, twice daily). Mansfield et al. (1993) demonstrated effective suppression of pubertal progression with nafarelin intranasal therapy, including arrest of breast development, normalization of growth velocity, and preservation of predicted adult height. The higher dose (4x the endometriosis dose) reflects the need for robust gonadotropin suppression in children, who may have higher GnRH drive during precocious puberty activation.
IVF Long Protocol Downregulation
Intranasal nafarelin is used in the IVF long protocol for pituitary downregulation before controlled ovarian stimulation. Starting in the mid-luteal phase (cycle day 21), nafarelin 400-800 mcg/day nasal spray suppresses endogenous LH and FSH, preventing premature LH surges during gonadotropin stimulation. Filicori et al. (1996) confirmed comparable IVF outcomes with nafarelin versus other GnRH agonist protocols.
Endometriosis and hypoestrogenic therapy
Nafarelin is a potent decapeptide GnRH agonist delivered intranasally. After an initial gonadotropin flare, chronic dosing down-regulates pituitary GnRH receptors, suppressing ovarian estrogen production and inducing a reversible hypoestrogenic state. Multiple danazol-controlled Phase III trials established equivalent efficacy to danazol for endometriosis lesion reduction and pain relief, with fewer androgenic and adverse lipid effects, supporting its approval (Synarel).
- Equivalent to danazol for reducing endometriosis and pelvic pain
- Favorable metabolic profile versus danazol (stable lipids, fewer androgenic effects)
- Hypoestrogenic side effects (hot flashes, bone density loss) limit duration to ~6 months
Central precocious puberty
In children with central precocious puberty, nafarelin suppresses the prematurely activated hypothalamic-pituitary-gonadal axis, lowering LH and sex steroids to prepubertal levels, halting pubertal progression and slowing skeletal maturation. Effects reverse after discontinuation, allowing puberty to resume, making it an established indication.
- Suppresses LH and sex-steroid levels to prepubertal range
- Arrests secondary sexual development and slows bone-age advancement
- Effects are reversible on stopping treatment
Safety Profile
Nafarelin shares the GnRH agonist class safety profile with additional considerations specific to intranasal delivery. Hypogonadal effects include hot flashes (90%), vaginal dryness, decreased libido, headache, emotional lability, and myalgia. Bone mineral density declines 2-6% during 6 months of treatment; most is recovered within 6-12 months of discontinuation. Nasal-specific adverse effects include rhinitis (10%), nasal irritation, sneezing after spray administration, and rarely epistaxis. A critical practical consideration is that nasal decongestant sprays (oxymetazoline, xylometazoline) must be avoided within 30 minutes of nafarelin administration, as they alter nasal mucosal blood flow and can significantly reduce nafarelin absorption. Upper respiratory infections with severe nasal congestion may transiently impair drug delivery. Breakthrough bleeding can occur if nasal congestion reduces effective dosing below the suppression threshold.
Pharmacokinetic Profile
Nafarelin — Pharmacokinetic Curve
Intranasal spray exclusivelyQuick Start
- Route
- Intranasal spray exclusively
Molecular Structure
- Formula
- C66H83N17O13
- Weight
- 1322.5 Da
- CAS
- 76932-56-4
- PubChem CID
- 53781
- Exact Mass
- 628.1610 Da
- TPSA
- 136 Ų
- H-Bond Donors
- 3
- H-Bond Acceptors
- 9
- Rotatable Bonds
- 7
- Complexity
- 832
Identifiers (SMILES, InChI)
InChI=1S/C28H27ClF2N2OS.C4H4O4/c29-20-6-9-27-23(15-20)19(2-1-3-26(34)18-4-7-21(30)8-5-18)14-24-25(33-12-10-32-11-13-33)16-22(31)17-28(24)35-27;5-3(6)1-2-4(7)8/h4-9,15-17,19,32H,1-3,10-14H2;1-2H,(H,5,6)(H,7,8)
RQUBTVZGOQXLSD-UHFFFAOYSA-NResearch Indications
Approved Indications
GnRH agonist that induces a hypoestrogenic state, reducing endometriotic lesions and associated pelvic pain; intranasal 200 mcg twice daily.
Suppresses premature LH and sex-steroid secretion to prepubertal levels in children, arresting secondary sexual development.
Other / Investigational Uses
Used off-label to shrink fibroids and reduce bleeding via estrogen suppression, often preoperatively.
Employed for pituitary down-regulation in controlled ovarian stimulation protocols.
Research Protocols
intranasal Injection
This bulky aromatic D-amino acid substitution confers approximately 200-fold greater potency than native GnRH — among the highest potency ratios of any clinically used GnRH agonist — enabling effective pituitary suppression via intranasal delivery despite the route's inherently low bioavailability.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 400-800 mcg, 200 mcg, 400 mcg, 800 mcg, 1600 mcg, 1800 mcg | Twice daily | 6 months(Route: Intranasal) |
oral
This trial was pivotal for FDA approval and established intranasal GnRH agonist therapy as a viable alternative to oral androgens. Oral decongestants (pseudoephedrine) are acceptable and do not significantly affect nasal absorption.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Nasal spray | 400 mcg, 800 mg | Per protocol | 6 months |
| Is FDA-approved for central precocious pu | 1600 mcg | Twice daily | — |
| Mid-luteal phase | 400-800 mcg | Per protocol | — |
| Nasal spray | 200 mcg | Per protocol | — |
topical
Q: Can I use nasal decongestants while taking nafarelin? A: Topical nasal decongestants (oxymetazoline, phenylephrine sprays) should not be used within 30 minutes of nafarelin administration.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Is FDA-approved for central precocious pu | 1600 mcg | Twice daily | — |
| Mid-luteal phase | 400-800 mcg | Per protocol | — |
| Nasal spray | 200 mcg | Per protocol | — |
| Morning | 400 mcg | Per protocol | — |
Interactions
Peptide Interactions
Low-dose norethindrone acetate (5 mg daily) or conjugated equine estrogen (0.625 mg) plus medroxyprogesterone acetate enables extended nafarelin therapy beyond 6 months by maintaining estradiol in the "therapeutic window" (30-45 pg/mL) — sufficient to protect bone and prevent vasomotor symptoms b...
What to Expect
What to Expect
Effects begin within hours of administration based on half-life of ~3 hours (intranasal)
Peak plasma concentration (Tmax) is reached 10-45 minutes after nasal spray administration.
After 14 days, confirm downregulation (estradiol <50 pg/mL, thin endometrium, no ovarian cysts).
Hormonal recovery occurs within 4-8 weeks of treatment discontinuation.
If amenorrhea is not achieved by month 2, dose may be increased to 800 mcg/day (one spray per nostril BID).
Quality Indicators
What to look for
- Phase 3 clinical trial data available
Caution
- Short half-life may require frequent dosing
Frequently Asked Questions
References (11)
- [4]
- [5]
- [1]Henzl MR et al Administration of nasal nafarelin as compared with oral danazol for endometriosis N Engl J Med (1988)
- [2]Mansfield MJ et al Long-term treatment of central precocious puberty with nafarelin J Pediatr (1993)
- [7]Donnez J et al — GnRH agonists versus oral GnRH antagonists for uterine fibroids and endometriosis Hum Reprod Update (2023)
- [3]
- [8]Neven et al — Long-term outcomes of GnRH agonist treatment in central precocious puberty Hum Reprod Update (2022)
- [9]Al-Inany et al — GnRH agonist versus antagonist protocols in IVF: updated Cochrane review Cochrane Database Syst Rev (2022)
- [6]Daya S Gonadotropin releasing hormone agonist protocols for pituitary desensitization in IVF Hum Reprod (2000)
- [10]The Nafarelin European Endometriosis Trial Group Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up (Nafarelin European Endometriosis Trial, NEET) Fertility and Sterility (1992)
→ In 307 women, intranasal nafarelin 200 mcg twice daily was as effective as danazol 600 mg/day at reducing endometriosis and symptoms over 6 months, with a more favorable metabolic profile.
- [11]Wu MH, et al. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan Journal of the Formosan Medical Association (2005)
→ In 59 women, nafarelin and danazol had similar clinical efficacy but nafarelin caused fewer laboratory changes and a stable lipid profile.
NADH
NADH (nicotinamide adenine dinucleotide hydride) is the reduced form of NAD+, a critical coenzyme involved in cellular energy production, redox reactions, and m
NAP Peptide (NAPVSIPQ)
NAP (sequence: NAPVSIPQ, Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) is an octapeptide representing the smallest active fragment of activity-dependent neuroprotective prot